ACell, Inc., a leading innovator in regenerative medicine, is headquartered in the United States, with significant operations across various regions. Founded in 1999, the company has established itself in the biotechnology industry, focusing on advanced wound care and surgical reconstruction solutions. ACell's core products, including its unique MatriStem® technology, utilise porcine-derived extracellular matrix to promote tissue regeneration and healing. This innovative approach sets ACell apart, offering effective solutions for complex wounds and surgical applications. With a strong market position, ACell has achieved notable milestones, including FDA approvals and partnerships that enhance its product offerings. The company continues to be at the forefront of regenerative medicine, committed to improving patient outcomes through its cutting-edge technologies.
How does ACell, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
ACell, Inc.'s score of 39 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ACell, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Integra LifeSciences Holdings Corporation, which may influence its climate commitments and emissions reporting. As of now, ACell, Inc. has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The absence of specific emissions data and reduction initiatives suggests that ACell may be in the early stages of developing its climate strategy. The emissions data and performance metrics for ACell are inherited from its parent company, Integra LifeSciences Holdings Corporation, which operates at a cascade level of 1. This relationship may provide a framework for future climate commitments and emissions reductions as ACell aligns with the broader sustainability goals of its parent organisation. In summary, while ACell, Inc. currently lacks specific emissions data and reduction targets, its affiliation with Integra LifeSciences Holdings Corporation may play a crucial role in shaping its future climate initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 13,902,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 18,609,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ACell, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.